Communications on Applied Nonlinear Analysis
ISSN: 1074-133X
Vol 32 No. 8s (2025)

# Enhancing Healthcare M&A Valuations Using Probabilistic Sensitivity Analysis

**Na Kyung Kim**

**University of Chicago (Chicago, IL, USA)**

**julia.nakyung.kim@gmail.com**

***Article History:***

***Received: 15-06-2025***

***Revised: 19-07-2025***

***Accepted: 10-08-2025***

**Abstract:**

Healthcare mergers and acquisitions (M&A) create strategic pathways for companies to advance product development, streamline integration, and drive innovation. Accurate valuation, therefore, lies at the heart of corporate strategic and financial decision-making, with different methodologies applied based on the nature of the transaction. Although existing valuation frameworks are flexible, dynamic, and widely adopted, the precision of healthcare company valuations is heavily impacted by factors such as regulatory frameworks, integration risks, reimbursement shifts, policy changes, and patient outcomes. Probabilistic Sensitivity Analysis (PSA) addresses some of these challenges by evaluating how uncertainty in input parameters affects valuation results through assigning probability distributions to those inputs, rather than relying on single-point estimates. This article explores the benefits of incorporating PSA into the valuation of healthcare companies and evaluates how PSA can enhance the reliability, transparency, and adaptability of traditional valuation approaches. We will specifically focus on comparing deterministic models with probabilistic methods such as Monte Carlo simulations, decision trees, and Bayesian frameworks. The paper further highlights real-world applications, critiques limitations, and identifies future research opportunities. We believe that integrating PSA into valuation processes for M&A transactions enables policymakers, acquirers, and healthcare investors to better navigate the complexities of high-risk M&A environments through promoting more informed and data-driven decision-making. We believe that PSA serves not only as a methodological enhancement but also as a strategic tool that bolsters stakeholder confidence and post-acquisition performance within an ever-changing healthcare landscape.

Keywords: Healthcare Mergers and Acquisitions (M&A); Valuation Models; Probabilistic Sensitivity Analysis (PSA); Monte Carlo Simulation; Risk Assessment in Healthcare Finance

## I. INTRODUCTION

Mergers and acquisitions (M&A) of healthcare companies have become one of the leading ways to promote growth through strengthening competitive moats and providing structural corrections in a complicated and highly controlled global healthcare economy [1]. In the last ten years, there has been a growing trend of healthcare companies spanning various verticals, such as pharmaceutical, medical devices, healthcare services, and life sciences tools & diagnostics, pursuing inorganic growth strategies to support growth and expansion, reduce operational expenses, diversify assets, and gain integrated care competencies [2]. However, the process of ascribing financial valuation to healthcare companies is often not a simple task. Healthcare companies are vulnerable to various risks that are difficult to quantify, such as clinical outcome variability, regulatory volatility, reimbursement and pricing fluctuations, and policy and political risks [3]. Deterministic models, including discounted cash flow (DCF), comparable companies analysis, and precedent transaction analysis, rely heavily on fixed-point estimation, which presupposes stability and predictability, reducing their accuracy in reflecting the uncertainties inherent in healthcare companies and transactions [4].

As a result, Probabilistic Sensitivity Analysis (PSA) has emerged as a systematic and statistical approach to valuation [5]. This method has seen growing adoption, progressing through multiple stages, beginning with initial standardization and methodological consolidation (2015-2017), followed by integration with Bayesian and non-linear modeling techniques (2018-2019), development of high-performance computational and hybrid frameworks (2020-2022), and, finally, emergence of AI-driven distribution modeling and enterprise-level implementation (2023-2024). These developments altogether illustrate the growing role and potential of PSA in advancing risk-adjusted, data-driven valuation methodologies within the finance and M&A landscape.


**Figure 1: Evolution of Probabilistic Sensitivity Analysis (PSA) from 2015 to 2024**

PSA modifies single-point estimation by employing probabilities to model key valuation drivers, such as projected revenues, patient volumes, regulatory exposure, integration costs, clinical outcomes, cost synergies, and reimbursement strategies [6]. Monte Carlo simulation, Bayesian inference, and probabilistic decision trees allow financial analysts to generate thousands of scenarios which help approximate risk-adjusted values and measure the probability of success and potential downside [7]. This method is highly consistent with the dynamic and fast-paced nature of healthcare markets, thus providing decision-makers with a clearer perspective on the projected value, variance, and the confidence interval of potential deals [8]. PSA supports better strategic planning, due diligence, and negotiation effectiveness in healthcare M&A transactions by improving strategic analysis and evidence-based assessment [9].

The expansion of PSA in healthcare valuation represents a paradigm shift toward data-focused financial evaluation powered by rapid technological advancements [10]. PSA allows systematic analysis of uncertainty in terms of payer-mix variability and competitive pressures, clinical outcomes variability, regulatory risk to new technologies and drugs [11]. The probabilistic model also enables the combination of subjective forecasts with empirical data and Monte Carlo outputs, such as confidence interval and risk-adjusted valuation range, which enhances the transparency of analysis and methodological quality [12]. These capabilities are particularly valuable in pharmaceutical and biotechnology acquisitions where uncertainties around drug development schedules, regulatory approvals, and pricing systems are high [13].

In provider and hospital transactions, PSA helps with conducting a reliable assessment of patient demand, capital expenditure needs, and operational integration complexities [14]. Altogether, PSA improves the accuracy, transparency, and robustness of healthcare M&A valuation by addressing and aiming to reduce various sources of uncertainty in an industry in a systematic manneaddressing and aiming to reducer [15].

### 1.1 Background on Healthcare M&A

Demographic shifts, technological changes, and rising regulatory scrutiny have introduced an array of inevitable structural changes to M&A processes in the healthcare industry [16]. Previously, M&A activity in healthcare was primarily aimed at achieving operational efficiencies, geographical growth, and service diversification. However, there has been a subsequent shift towards value-based care models, heightened usage of digital health technologies, telemedicine, and growing applications of clinical decision-making models which have introduced changes to M&A rationale [17]. Organizations are also increasingly seeking acquisitions to build integrated delivery systems, enhance supply chain efficiencies, gain pricing power with payers, and access technological capabilities that would be costly or time-consuming to develop in-house [18]. Despite the prevalence of healthcare M&A transactions, valuing healthcare companies is a uniquely complex process, since it is based on reimbursement, quality indices, and clinical performance models, along with outcome-based revenue models [19]. Valuation uncertainty must account for clinical performance, patient safety, regulatory compliance, and integration of infrastructure, particularly in the case of an acquisition of special facilities or introduction of technology-intensive providers [20]. Such uncertainties cannot be adequately characterized by deterministic valuation techniques; probabilistic approaches, such as PSA, are better suited as they explicitly model uncertainty.

This paper examines PSA's ability to enhance the transparency, strength, and reliability in healthcare company valuation. PSA aids in strategic and operational decision-making by generating probability-based insights into future performance, downside risk, and confidence intervals for forecasted cash flows. To better address multidimensional risk in valuation models, the literature review examines the opportunities afforded by PSA-based techniques, including Monte Carlo simulation, Bayesian inference, stochastic modeling, and probabilistic decision analysis. PSA integrates finance, health economics, and decision science perspectives by combining financial modelling with clinical data variability, interaction effects, and formal risk assessment systems. In this case, PSA represents a paradigm shift toward more comprehensive and evidence-based valuation practices, which can enable acquirers, investors, and regulators to make more informed decisions under the continuously uncertain healthcare markets.

Practical examples of PSA application across various healthcare transaction types, including hospital acquisitions, pharmaceutical and biotechnology mergers, medical device deals, and digital health deals, are also evaluated in this review. Each subsector possesses distinct sources of uncertainty that significantly affect valuation. Biotechnology and pharmaceutical transactions must contend with drug pipeline development risk, regulatory clearance uncertainty, exclusivity duration, and pricing trends. The technology adoption rates, cybersecurity vulnerabilities, legal classification, and interoperability pose valuation uncertainties regarding the valuation dynamics of digital health acquisitions. Hospital acquisitions also involve uncertainty around patient volume, payer mix, workforce performance, operational efficiency, and post-merger integration outcomes. These varied contexts allow for an assessment of how adaptable PSA is across the healthcare M&A environment and enable comparison of its effectiveness with traditional risk assessment tools. PSA enables decision-makers to quantify downside risk, model probability-weighted returns, and stress-test acquisition strategies under various circumstances. The quality of data, modelling choices, and selection of appropriate probability distributions are also areas of concern addressed in this review. Additionally, emerging trends such as combining PSA with artificial intelligence, machine learning, and predictive analytics are discussed, as they may further refine valuation accuracy. Overall, the review provides a forward-looking appraisal of PSA applications in healthcare M&A valuation.

## II. FUNDAMENTALS OF HEALTHCARE M&A VALUATION

The valuation during mergers and acquisitions is a complicated process because it involves consideration of financial, clinical, operational, and regulatory objectives that are interdependent and that dictate long-term sustainability of a given acquisition [21]. Healthcare organizations operate in a non-monolithic environment, such as the traditional industries, in terms of revenue streams, as they are governed by reimbursement systems, accreditation, payer-mix, cost-containment, and evidence-based clinical norms [22]. This has compelled valuation practitioners to incorporate a wider range of variables into their models, such as patient-mix factors, diagnostic accuracy, treatment quality measures, technology maturity, and regulatory compliance indicators [23]. Traditional deterministic valuation models do not typically account for the uncertainty within this interdependent and multidimensional set of parameters, limiting their predictive power in healthcare M&A scenarios [24]. Accordingly, this section presents industry-specific valuation principles and risk factors, while illustrating the weaknesses of deterministic methods in capturing uncertainty in healthcare transactions [25]. To establish the analytical rationale for using PSA, the section examines classical valuation models, industry-specific sources of volatility, and the increasing role of clinical and operational data in modern valuation activities [26].




**Figure 2: Conceptual Framework for Healthcare M&A Valuation**

Figure 2 is a multidimensional healthcare mergers and acquisitions valuation framework that is designed based on four domains: financial, clinical, operational, and regulatory. Each area has industry-specific input variables, which have a significant impact on valuation results, such as reimbursement policies, payer- and patient-mix variability, diagnostic accuracy, treatment effectiveness, technology maturity, and regulatory compliance indicators. The variables are interdependent and stochastic in nature, producing non-linear impacts on projected cash flows and risk profiles. The model formally demonstrates that deterministic valuation models based on fixed-point approximations and static assumptions are inadequate to reflect the compounded and layered uncertainty of healthcare transactions. As a result, the framework advocates for PSA as a methodological extension in which parameter uncertainty is explicitly modeled using probability distributions, enabling scenario-based valuation under uncertainty.

### 2.1 Valuation Techniques in Healthcare Transactions

The set of valuation methodologies used in the healthcare industry is grounded in corporate finance principles but requires significant adaptation to the sector's unique characteristics. The diverse nature of healthcare institutions, such as hospitals and diagnostic companies, biotechnology companies, insurance firms, and digital health companies, requires valuation methods that are specific to business models, clinical operating structure, regulatory risk profile, and innovation cycles. Traditional valuation methods, including discounted cash flow (DCF), comparable company analysis (CCA), and precedent transaction analysis (PTA), must therefore be adapted to capture variability in reimbursement mechanisms, clinical outcomes, operational efficiency, and development pipeline risk. Table 1 provides a systematic summary of commonly used healthcare valuation techniques and their analytical foundations.

**Table 1: Common Healthcare M&A Valuation Techniques**

| **Valuation Method** | **Core Idea** | **Strengths** | **Limitations in Healthcare** |
|---|---|---|---|
| **Discounted Cash Flow (DCF)** | Forecasting future cash flows and discounting them to present value | Captures long-term value; sensitive to operational nuances | Highly sensitive to reimbursement changes, patient volumes, and regulatory shifts |
| **Comparable Company Analysis (CCA)** | Benchmarking valuation ratios against peer organizations | Easy to apply; market-driven | Hard to find true peers due to heterogeneity in healthcare service lines |

| | | | |
|---|---|---|---|
| **Precedent Transactions Analysis (PTA)** | Using past M&A deals as valuation benchmarks | Reflects real transaction behavior | Past deals may not reflect current regulatory or clinical realities |
| **Real Options Valuation** | Future value opportunities under uncertainty | Useful for biotech, R&D-driven firms | Requires complex modeling and high-quality probability data |
| **Synergy and Integration Valuation** | Assesses cost savings and revenue gains post-acquisition | Predicts real strategic benefits | Integration in healthcare is risky due to culture, workflow, and IT challenges. |

Healthcare M&A valuation approaches are each strong within their context yet are limited by uncertainty arising from payer-mix differences, reimbursement risk, and the complexity of clinical operating environments. DCF, CCA, PTA, real options valuation, and synergy-based models are all highly sensitive to case-mix fluctuations, technology adoption levels, clinical trial outcomes, and post-merger integration risk. These limitations underscore the need for probabilistic sensitivity analysis in order to make uncertainty explicit in parameters and to provide a representation of the potential outcomes of possible valuations in case of stochastic healthcare conditions.

### 2.2 Common Challenges and Risk Factors in Valuation

The multi-layered risk factors affecting healthcare valuation extend well beyond traditional financial indicators. Dependence on regulatory processes, variability in clinical outcomes, the rate at which technology is adopted, workforce capability, and the dynamism within the market are factors that contribute to sector volatility. These sources of uncertainty propagate through valuation models, affecting revenues, costs, integration timelines, and long-term strategic viability. When constructing valuation frameworks, these risks must be clearly conceptualized and systematically addressed, especially given the inadequacy of conventional point-estimate methods. Table 2 presents the key sources of risk relevant to healthcare valuation and their implications for M&A analysis.

**Table 2: Major Risk Categories in Healthcare M&A Valuation**

| **Risk Category** | **Description** | **Impact on Valuation** |
|---|---|---|
| **Regulatory Risk** | Changes in reimbursement, compliance standards, or health policy | Alters revenue streams; impacts long-term sustainability |
| **Clinical Quality Risk** | Variability in patient outcomes, readmission rates, and infection control | Affects payer incentives, reputation, and service demand |
| **Operational Integration Risk** | EHR compatibility, workflow alignment, staffing, and IT systems | Can trigger cost overruns and operational disruptions |
| **Technological Risk** | Adoption of AI tools, medical devices, and cybersecurity requirements | Raises capital expenditure; introduces uncertainty |

| | | |
|---|---|---|
| **Market and Demographic Risk** | Shifting patient demographics, evolving disease patterns, and changing competition dynamics | Influences demand forecasting and service capacity |
| **External Event Risk** | Pandemics, economic downturns, and supply chain instability | Causes sudden, high-impact volatility |

These risk dimensions explain why the healthcare valuation needs a more flexible and probabilistic model of its operations, as compared to the approaches used in most other industries. Regulatory change is among the greatest sources of volatility, as it can occur abruptly and unpredictably, altering compliance requirements, reimbursement rules, and policy frameworks. Clinical quality risk directly affects revenue generation through reimbursement penalties, litigation exposure, and reputational harm. Operational integration risk has also grown due to the complexity of care delivery processes and the use of highly specialized, tightly regulated information systems. Simultaneously, the growing use of AI-based diagnostics, telemedicine, robotics, and heightened cybersecurity requirements has amplified technological uncertainty. Market and demographic forces present further forecasting challenges, particularly given population aging and the rising prevalence of chronic disease. Moreover, exogenous shocks such as global pandemics can rapidly invalidate operating assumptions and render deterministic valuation forecasts obsolete.

Taken together, these factors demonstrate the weaknesses of point-estimate-based valuation approaches and support the use of PSA to explicitly represent uncertainty and model asymmetric risk exposure. This asymmetry can be depicted in Figure 3 through the mapping of the key healthcare M&A valuation risks based on their relative impacts and probability of occurrence. Regulatory and clinical quality risks fall within the high-impact, medium-to-high likelihood quadrant, while technology-related uncertainty and external shock events occupy the high-impact, low-predictability area. This distribution of risks demonstrates the non-linearity and asymmetry of healthcare valuation risk, which also justifies the use of probabilistic models as opposed to deterministic frameworks.




**Figure 3: Risk modelling pipeline for probabilistic valuation.**

**2.3 Role of Financial, Operational, and Clinical Metrics**

The valuation of healthcare organizations should be based on a combined evaluation of financial, operational, and clinical performance measures. Conventional valuation models rely primarily on financial metrics, including EBITDA, cash flow stability, payer-mix composition, accounts receivable cycles, and cost-to-revenue ratios.

Although these metrics remain fundamental, they cannot be applied in isolation within the healthcare setting. Operational performance measures, such as bed occupancy rates, surgical and procedural capacity utilization, staff productivity ratios, technology utilization efficiency, and overhead cost allocation, provide critical insight into organizational scalability, efficiency, and post-acquisition integration requirements. These metrics help evaluators determine whether a target organization is well-run or will require substantial operational restructuring following acquisition.

The shift toward value-based care has also increased the relevance of clinical performance measures in valuation analysis. The key indicators include patient satisfaction scores, clinical outcome measures, readmission rates, treatment success ratios, and adherence to evidence-based clinical guidelines. Clinical performance directly influences reimbursement rates, payer relationships, and institutional reputation, making it a vital determinant of long-term value creation. Incorporating financial, operational, and clinical measures into valuation models enables acquirers to develop a comprehensive picture of the economic sustainability and care delivery performance of a target organization, thereby informing more data-driven and well-grounded acquisition decisions.

**III. OVERVIEW OF PROBABILISTIC SENSITIVITY ANALYSIS (PSA)**

PSA has become a major analytical instrument for addressing the multidimensional uncertainty inherent in healthcare M&A valuation [27]. Traditional healthcare valuation approaches tend to impose constraining assumptions by treating complex, non-linear, and interdependent operational processes as fixed or linearly projected inputs in deterministic models [28]. PSA represents a methodological shift that replaces point estimation with a probabilistic model, in which key uncertain variables, such as patient volume, reimbursement rates, integration costs, clinical outcome variability, and regulatory change, are characterized by statistical distributions rather than deterministic values [28,29].

PSA allows analysts to generate large numbers of simulated valuations through Monte Carlo simulation and other probabilistic methods, thereby estimating the full distribution of possible values rather than just the expected value. This method supports the identification of major sources of variance, evaluation of tail risk and downside exposure, and the creation of probability-weighted decision frameworks. Explicitly propagating uncertainty across both financial and clinical dimensions increases the transparency and rigor of the analytical process, revealing expected value distributions, confidence intervals, and asymmetric risk profiles. This strictness is especially important in healthcare M&A, where small variations in regulatory policy, clinical performance, or payer behavior can have disproportionately large impacts on valuation results, as in Figure 4.




**Figure 4: Conceptual Flow of Probabilistic Sensitivity Analysis**

In addition to its statistical rigor, PSA elevates executive decision-making by reframing valuation through probability-based risk and return models rather than deterministic best- and worst-case point estimates. This probabilistic framing is particularly relevant in healthcare M&A, where acquirers must navigate interdependent sources of uncertainty across clinical performance, operational integration, regulatory compliance, and demographic dynamics. PSA facilitates explicit comparison of alternative deal structures, integration approaches, and strategic paths across different uncertainty scenarios, thereby supporting the design of acquisition structures that are more resilient to adverse outcomes. Moreover, PSA enables quantification of value-at-risk (VaR), assessment of debt service capacity, and estimation of the likelihood of achieving pre-established financial and operational performance thresholds under varying policy, reimbursement, and market conditions. These capabilities are particularly valuable in post-pandemic settings characterized by high uncertainty and structural change, particularly where private equity investors, hospital systems, and payer-provider platforms are involved.

Another role of PSA is as an integrative analytical framework that bridges the historical gap between corporate finance valuation and health outcomes research by combining financial models with clinical and operational data. PSA, when used with Monte Carlo simulation, Bayesian updating, or real-options analysis, can be applied iteratively as new information emerges, including updated clinical quality measures, payer mix changes, or regulatory developments, which can enable dynamic recalibramic recalibration of valuation profiles instead of being regarded as a fixed projection. This iterative nature makes PSA especially appropriate when service-line performance (e.g., oncology or orthopedics), care model innovation, or multi-site integration with heterogeneous cost structures must be considered. As healthcare M&A continues to grow alongside value-based reimbursement and data-intensive integration models, PSA offers a robust methodological framework for quantifying uncertainty and aligning valuation logic with emerging clinical, operational, and regulatory realities.

### 3.1 Definition and Theoretical Foundations

PSA is a quantitative approach that addresses uncertainty in model-based decision-making by explicitly modeling variability in input parameters. This method assigns statistical probability distributions to model inputs and propagates these uncertainties through repeated simulations to determine their overall effect on model outputs. PSA is grounded in Bayesian probability theory, stochastic modeling, and risk analysis, treating uncertainty as an inherent feature of complex systems rather than an exception. Under PSA, uncertain parameters are characterized by underlying probability distributions, including normal, triangular, beta, lognormal, or uniform, among others, with the choice guided by empirical evidence, expert judgment, or a combination of both [28]. PSA produces a distribution of valuation results from thousands of simulation runs, enabling the estimation of expected values, confidence intervals, tail risk, and the sensitivity of valuation outcomes to individual input parameters. PSA is especially applicable in healthcare and medical M&A transactions to model uncertainty in clinical outcomes, patient population dynamics, regulatory decisions, technological performance, and operational integration [29]. The conceptual power of PSA lies in its ability to combine statistical rigor with practical applicability. As a result, valuation outcomes more accurately reflect the stochastic nature of healthcare systems and the inherent uncertainty of strategic investments.

### 3.2 Distinction Between Deterministic and Probabilistic Approaches

Deterministic valuation methods rely on predetermined inputs and produce a single-point estimate of value, offering analytical simplicity but limited realism in highly uncertain environments such as healthcare. By contrast, probabilistic modeling explicitly captures the inherent dynamism of healthcare variables arising from operational variability, clinical outcome uncertainty, regulatory change, and exposure to exogenous shocks. Rather than assigning fixed values to uncertain inputs, probabilistic models attach statistical distributions to key parameters and compute a range of possible valuation outcomes through simulation-based analysis [30]. This methodology characterizes the full valuation distribution, including expected values, confidence intervals, and tail outcomes such as best-case, worst-case, and most-likely scenarios. The key distinction is that deterministic approaches suppress uncertainty by reducing it to a single-point estimate, whereas probabilistic approaches treat uncertainty as an inherent component of the analytical model. Table 3 presents a structured comparison of deterministic and probabilistic valuation methods in healthcare M&A.

**Table 3: Deterministic vs Probabilistic Valuation Approaches**

| Dimension | Deterministic Approach | Probabilistic Approach (PSA) |
|---|---|---|
| **Treatment of Uncertainty** | Assumes fixed inputs | Model's variables as statistical distributions |
| **Output** | Single valuation result | Range of outcomes with probability density |
| **Risk Visibility** | Low | High; quantifies downside risk |
| **Model Behavior** | Linear and static | Nonlinear and dynamic |
| **Decision Support** | Limited, based on fixed scenarios | Robust supports scenario-based and distribution-based decisions |
| **Suitability for Healthcare** | Poor in volatile contexts | Highly suitable for complex, uncertain environments |

### 3.3 Key PSA Methods (Monte Carlo, Bayesian Analysis, etc.)

PSA encompasses a collection of computational methods used to quantify uncertainty and risk in financial and clinical decision-making models. Monte Carlo simulation is the most widely used method; it involves repeated random sampling from specified probability distributions assigned to uncertain input variables to generate a large number of possible valuation outcomes [31]. This is a simulation-based method that allows estimating the distribution of outcomes, the variance, tail risk, and sensitivity to specific inputs. Bayesian analysis offers a complementary probabilistic framework by incorporating prior knowledge or beliefs and updating parameter estimates as new data becomes available. This dynamic updating property makes Bayesian approaches especially appropriate in healthcare M&A contexts where clinical evidence, regulatory decisions, or reimbursement policies are subject to change. Probabilistic decision trees are used to represent branching uncertainty related to clinical care pathways, regulatory approval events, or operational integration scenarios, enabling analysts to evaluate sequential decision points under uncertainty [32]. Together, these PSA methods form a multi-method analytical framework for healthcare M&A valuation, allow for the express quantification of uncertainty, evaluation of extreme-event risk, and recognition of key drivers of financial and strategic risk. Table 4 provides an overview of the key methods used in PSA and their common applications in healthcare valuation.

**Table 4: Key Methods Used in Probabilistic Sensitivity Analysis**

| Method | Core Concept | Application in Healthcare M&A |
|---|---|---|
| **Monte Carlo Simulation** | Random sampling across thousands of iterations | Evaluating revenue uncertainty, integration costs, and clinical variability |
| **Bayesian Analysis** | Updating beliefs using prior and new data | Modeling clinical trial outcomes and regulatory approval likelihood |

| | | |
|---|---|---|
| **Probabilistic Decision Trees** | Mapping uncertainty through branching pathways | Assessing multi-step acquisition risks (regulatory, clinical, operational) |
| **Stochastic Modeling** | Time-based random processes | Forecasting long-term patient demand and reimbursement changes |
| **Markov Models** | State-transition probability modeling | Used in acquisitions involving chronic care, oncology, and long-term care |

**IV. APPLICATION OF PSA IN M&A VALUATIONS**

PSA continues to play an increasingly important role in healthcare M&A valuation, particularly in settings characterized by high operational variability, clinical outcome uncertainty, and regulatory change [33]. Conventional valuation models typically rely on fixed assumptions for key inputs, including cash flows, patient demand, integration costs, reimbursement rates, and clinical performance, thereby underestimating risk and overstating confidence in their forecasts [34]. PSA addresses this methodological weakness by converting fixed input assumptions into stochastic probability distributions, enabling valuation to be expressed as a distribution of possible outcomes rather than a single deterministic estimate. PSA enables more rigorous evaluation of valuation risk by explicitly quantifying and propagating uncertainty, promoting risk-informed and evidence-based decision-making. This probabilistic approach enhances the accuracy and reliability of healthcare M&A valuation by modeling the range, probability, and asymmetry of potential valuation outcomes across a variety of clinical, operational, and regulatory conditions.

**4.1 PSA in Traditional M&A Financial Modeling**

Conventional M&A valuation models, including DCF, CCA, and PTA, are built on fixed assumptions regarding revenue growth, cost structures, and regulatory stability. These deterministic frameworks are enhanced when augmented with PSA by assigning probability distributions to critical valuation inputs, such as growth rates, operating margins, integration costs, and regulatory compliance costs [35]. Monte Carlo simulation is then used to generate large samples of valuation outcomes and produce probability-based estimates of value, downside risk, and the sensitivity ranking of key drivers. This integration transforms traditional deterministic models into risk-aware valuation instruments that more effectively inform transaction pricing, deal structuring, earn-out design, contingency planning, and post-merger integration strategies.

**4.2 Incorporating Uncertainty in Healthcare Revenue Projections**

The complexity of revenue forecasting in healthcare stems largely from its sensitivity to a range of interconnected factors, including clinical outcomes, payer-mix composition, reimbursement policy, disease prevalence, patient behavior, and competitive dynamics. This variability is frequently too complex to be captured through fixed-point assumptions; PSA addresses this by replacing deterministic inputs with statistically defined probability distributions. Common distributional modeling is of normal distributions of patient volumes, triangular distribution of reimbursement uncertainty, lognormal distribution of revenue-based clinical outcome variability, and binomial distribution of discrete clinical event probabilities [35]. Simulation outputs produce a probabilistic revenue envelope that defines the range of volatility, identifies high-risk service lines, and quantifies sensitivity to changes in clinical performance and regulatory conditions. This distributional perspective supports more accurate valuation and informs negotiation strategies and post-acquisition planning by clearly illustrating the range of possible revenue outcomes and their associated probabilities [36].

### 4.3 Modeling Integration Risks and Post-Acquisition Performance Using PSA

Integration risk is a critically important yet frequently underestimated aspect of healthcare M&A, as post-acquisition success depends on the ability to align operations across clinical, organizational, and technological dimensions. PSA offers a rigorous guideline on quantifying this uncertainty by giving probability distributions to major variables in the integration, such as EHR interoperability, workforce retention rates, workflow transition efficiency, organizational culture alignment, technology adoption timelines, and implementation costs [37]. Unlike deterministic valuation techniques, PSA models the non-linear and interdependent relationships among these factors, such as workflow delays in migration, which can decrease patient throughput, interrupt the reimbursement, and increase operating costs, all at the same time. Through Monte Carlo simulation or Bayesian updating, PSA enables estimation of the likelihood of synergy realization, the expected value and skewness of integration costs, and the time-to-value profile of post-merger integration. This probabilistic approach helps acquirers plan more effectively by enabling them to anticipate integration bottlenecks, provision contingency reserves, structure performance-based earn-outs, and design governance mechanisms capable of managing volatility [38]. By providing a realistic portrayal of post-merger uncertainty, PSA improves evaluation of both the financial attractiveness and operational viability of transactions involving hospital systems, biopharmaceutical R&D integrations, and digital health acquisitions, thereby reinforcing sound investment decision-making in complex healthcare deals.

## V. BENEFITS OF PSA IN HEALTHCARE M&A

PSA has made a significant methodological contribution to healthcare M&A valuation by providing a more realistic and data-driven treatment of uncertainty than traditional deterministic models [39]. Healthcare transactions take place in highly dynamic environments shaped by regulatory changes, clinical outcome variability, evolving payer arrangements, integration risk, and rapidly advancing technology. By explicitly modeling these sources of uncertainty, PSA allows decision-makers to assess the full distribution of possible valuation outcomes, rather than relying on oversimplified assumptions that understate risk exposure [40]. Through the assignment of statistical distributions and simulation-based analysis, PSA supports more sophisticated scenario planning and financial resilience by revealing the primary drivers of valuation volatility across thousands of simulated future states. This probabilistic approach advances strategic and operational decision-making by producing probability-weighted estimates of expected performance, downside risk scenarios, and confidence intervals for projected cash flows. This transparency reinforces internal governance, shapes negotiation strategy, and enhances credibility with external stakeholders, including investors, regulators, and financial institutions. Ultimately, by making uncertainty an explicit component of valuation, PSA enhances the validity of healthcare M&A assessments, supports more informed capital allocation decisions, and improves the likelihood of long-term acquisition success.

**Table 5: Key Benefits of Probabilistic Sensitivity Analysis (PSA) in Healthcare M&A**

| Benefit Category | Core Contribution | Key Statistical Outputs | Impact on M&A |
|---|---|---|---|
| Improved Risk Assessment and Scenario Planning | Models uncertainty using probability distributions and Monte Carlo simulations | Percentile bands, PDFs, VaR, scenario variance | Strengthens risk visibility and prepares organizations for best/worst-case outcomes |
| Enhanced Decision-Making for Stakeholders | Provides probability-weighted valuations and sensitivity measures | Expected Value, Sensitivity Index, tornado outputs | Improves strategic decisions, board alignment, and negotiation leverage |

| | | | |
|---|---|---|---|
| Increased Transparency and Investor Confidence | Makes assumptions explicit and quantifies uncertainty ranges | Confidence Intervals, AIC/BIC, risk exposure metrics | Builds investor trust, supports due diligence, and enhances valuation credibility |

## VI. CHALLENGES AND LIMITATIONS OF PSA

PSA is not without limitations in healthcare M&A valuation, particularly given the complexity and data-intensive nature of the healthcare environment. Successful application of PSA requires high-quality data, substantial computational capacity, advanced analytical expertise, and effective communication frameworks to ensure probabilistic results are properly interpreted [34]. Many healthcare organizations lack the data infrastructure or analytical maturity needed to define appropriate probability distributions for key variables such as reimbursement volatility, patient demand dynamics, regulatory compliance costs, and clinical outcome variability. Even when data are available, the translation of empirical findings into statistically valid distributions often involves subjective judgment, which can affect model outcomes and introduce bias [35,38]. PSA models also become computationally intensive as problem dimensionality increases, particularly in transactions involving numerous uncertain parameters, multi-stage integration processes, or complex clinical interactions. This computational burden can pose scalability constraints when applying PSA to large healthcare systems or diversified M&A portfolios. Moreover, probabilistic outputs such as density functions, percentiles, and value-at-risk metrics can be difficult to interpret for executives, clinicians, or investors without formal statistical training. Misinterpretation or miscommunication of probabilistic results can compromise the usefulness of PSA and lead to suboptimal strategic decisions [39,40]. Acknowledging these methodological limitations is essential to ensuring that probabilistic valuation methods strengthen rather than undermine decision-making in healthcare M&A contexts.

### 6.1 Data Quality and Availability Issues

Data quality and consistency are critical to the successful application of PSA; however, healthcare systems frequently rely on fragmented, incomplete, and heterogeneous data. Clinical documentation practices vary widely across organizations, and payer reimbursement data and operational performance reports are often insufficiently standardized, diminishing the accuracy with which probability distributions can be specified [34]. In numerous healthcare organizations, longitudinal data availability is further limited by EHR system transitions, organizational mergers, outdated platforms, and data silos. Additional data challenges, including missing values, unstructured clinical narratives, manual data entry errors, and inconsistent reporting, further undermine data reliability. These data quality constraints directly and negatively affect PSA outputs, as simulation accuracy depends on the validity of the input distributions. Incomplete or inconsistent data can lead to biased parameter estimates, distorted risk profiles, and unreliable valuation ranges, ultimately undermining PSA's credibility as a decision-support tool in healthcare M&A valuation [35].

### 6.2 Computational and Model Complexity

As the number of uncertain parameters, interdependencies, and non-linearities increases, so do the computational demands of PSA models. Running millions of Monte Carlo simulation iterations requires substantial processing power, especially when incorporating Bayesian updating, real-options models, or nested probabilistic structures. Many small and mid-sized healthcare organizations lack the analytical infrastructure and technical expertise in statistics, probability theory, and healthcare systems modeling needed to effectively implement such methods [36]. Moreover, PSA models also require careful attention to the specification of model structure and input distributions since imprecise specification can yield biased valuation estimates or imprecise output distributions. Inadequate model design, insufficient validation, or poor calibration can compromise the validity of the analysis. The robustness and complexity of PSA therefore contribute to higher implementation costs and an increased risk of inaccurate or unreliable valuation outcomes, particularly when rigorous model governance and validation procedures are not followed [37].

### 6.3 Interpretation and Communication of Results

PSA outputs, such as probability distributions, valuation intervals, and risk curves, may be difficult to interpret for non-technical stakeholders. When reviewing probabilistic outputs, executives, clinicians, and investors may misinterpret confidence intervals, underestimate tail risk events, or fail to grasp the significance of variance. Because PSA presents valuation as a distribution of potential outcomes rather than a single-point estimate, its results can be at odds with traditional decision-making norms, particularly in negotiations, capital allocation discussions, and strategic planning. Misinterpretation of probabilistic outputs may lead to excessive caution or undue optimism, which in turn distorts M&A strategies and risk assessments. Effective use of PSA therefore requires systematic interpretation frameworks, clear translation of statistical results into concrete scenarios, explicit articulation of key assumptions, and stakeholder training in probabilistic reasoning. Without proper contextualization and a sound communication and governance framework, the practical value of PSA outputs may be limited, reducing their impact on strategic decision-making despite their analytical rigor.

### 6.4 Model Structure Limitations and Assumption Sensitivity

PSA is highly sensitive to both the assumed probability distributions and the overall structure of the model. In practice, constructing input distributions is often a subjective process, particularly in settings with limited historical data or conflicting expert opinions [31-34]. Poor distributional choices, such as assuming a normal distribution for variables that are skewed and better modeled by lognormal or beta distributions, can significantly distort simulation results and undermine valuation accuracy. Moreover, PSA is inherently constrained in its ability to identify unknown unknowns, such as unexpected regulatory changes, sudden population health shocks, or unanticipated disruptive technologies. Model structural design also introduces risk, as complex clinical, operational, and regulatory interactions may be simplified to achieve tractability, creating an illusion of precision. Omitted dependencies, excluded variables, or incorrectly specified relationships can produce false confidence intervals and distorted valuation distributions. PSA outputs should therefore be interpreted with careful attention to model assumptions, validation procedures, and sensitivity diagnostics. When designed and managed rigorously, PSA can enhance strategic and operational decisions by offering probability-based insights into expected performance, downside risk, and confidence levels around projected cash flows, provided that its limitations are clearly recognized.

## VII. EMERGING TRENDS AND FUTURE DIRECTIONS

The adoption of PSA in healthcare M&A valuation is occurring against a backdrop of rapid change in analytical technologies, regulatory frameworks, and clinical data ecosystems. Increases in computational power, data processing capability, and the emergence of machine learning-based analytics are expanding the scope of probabilistic modeling, enabling more accurate and granular representation of uncertainty across financial, operational, and clinical dimensions [33-37]. At the same time, the proliferation of digital health solutions, AI-based diagnostics, and value-based care models is increasing the complexity of healthcare transactions, making probabilistic valuation methods not only beneficial but increasingly necessary. Looking ahead, PSA applications are expected to advance beyond static risk quantification toward real-time probabilistic forecasting, scenario-based regulatory analysis, and semi-automated valuation scenario generation. As policymakers demand greater transparency in financial and clinical performance reporting and investors require empirically grounded due diligence, PSA is becoming an integral component of sophisticated valuation practices [38-40]. This positions PSA to enhance strategic and operational decision-making and align valuation practices with the emerging data-driven realities of the healthcare sector by providing probability-weighted estimates of expected performance, downside risk scenarios, and confidence intervals over the projected cash flows.

### 7.1 Integration with Artificial Intelligence and Machine Learning

The combination of PSA with ML and AI tools provides a significant advancement in healthcare M&A valuation by enhancing distributional accuracy, identifying non-linear relationships, and automating uncertainty quantification across high-dimensional data. Machine learning algorithms can extract information from EHRs, claims databases, operational performance metrics, and clinical trial data, enabling more empirically grounded specification of PSA input distributions than traditional parametric assumptions allow. Such data-driven distributions improve simulation precision and reduce subjectivity. Deep learning architectures also support PSA functionality by enabling continuous, real-time updating of probabilistic models as new clinical, operational, or regulatory information becomes available, transforming PSA from a static analytical framework into an adaptive valuation structure. Reinforcement learning and Bayesian neural networks can model long-horizon uncertainty, including regulatory evolution, reimbursement dynamics, and multi-period performance trajectories. The integration of AI/ML with PSA will produce predictive, self-updating valuation models capable of addressing the dynamic clinical, financial, and operational complexity of healthcare mergers and acquisitions.

### 7.2 Use in Regulatory and Policy Evaluation

PSA is becoming increasingly relevant for assessing the financial consequences of regulatory policies, clinical guidelines, and compliance frameworks in healthcare, particularly where reimbursement mechanisms and regulatory uncertainty significantly affect financial viability. PSA offers policymakers and analysts a statistical framework for measuring the distributional effects of regulatory changes, modeling market disruption, and estimating the economic consequences of regulatory policy uncertainty. Through systematic analysis of policy-induced volatility, PSA enables regulatory variables to be treated as stochastic inputs rather than fixed deterministic parameters. PSA can model the uncertainty arising from changes in Medicare and Medicaid reimbursement rates, insurance coverage requirements, accreditation standards, and compliance requirements, providing investors and acquirers with actionable, probability-weighted estimates of regulatory risk. As healthcare systems move toward value-based care models, PSA also helps evaluate uncertainty surrounding quality-based performance measures, incentive alignment, and outcomes-based payment systems. By incorporating regulatory variability dynamics, PSA strengthens evidence-based decision-making for regulators, investors, and market participants and enhances the alignment of valuation practices with evolving policy and reimbursement landscapes.

### 7.3 Opportunities for Further Research

Future research is likely to advance PSA toward hybrid methodological models that combine stochastic simulation with deep learning-based forecasting for more realistic representation of clinical and operational complexity. Such architectures could use machine learning models as high-fidelity predictors of uncertain inputs, enabling more efficient and empirically informed specification of probability distributions in PSA. Further methodological development may include sector-specific probabilistic models for biotechnology, pharmaceuticals, digital health, and provider organizations, as well as more sophisticated sensitivity analysis approaches capable of explicitly capturing interdependencies and feedback interactions among uncertain variables. PSA may also be integrated with real options pricing, Markov decision processes, and multi-agent simulation models to improve the modeling of long-horizon investment uncertainty, such as R&D pipeline valuation or chronic care pathway economic analysis. Another promising research direction involves improving the visualization of probabilistic outputs to enhance interpretability and communicate uncertainty more effectively to decision-makers. Together, these research directions suggest that PSA will continue to mature and become more sophisticated, scalable, and widely applied across healthcare M&A and other strategic investment contexts.

## VIII. CONCLUSION

Healthcare mergers and acquisitions in recent years have increasingly called for more sophisticated valuation methods, specifically PSA, as a methodology better suited to the growing uncertainty of the industry. PSA is particularly well-suited to healthcare transactions characterized by high regulatory complexity, heterogeneous clinical outcomes, and diverse operational structures. While traditional deterministic valuation models remain foundational, they cannot be applied broadly without limitation, as they fail to account for the layered and interacting risks of healthcare M&A transactions. By contrast, PSA provides a rigorously probabilistic framework that explicitly models uncertainty across financial, operational, and clinical dimensions, transforming complex risk structures into interpretable valuation distributions, scenario spaces, and exposure measures. By applying the application of Monte Carlo simulation, Bayesian inferences, stochastic modeling, and probabilistic decision trees in order to build dynamically informed decision support systems.

The analysis reveals that PSA strengthens in strengthening risk perception and strategic planning while enhancing transparency and stakeholder trust among investors, regulators, and acquiring companies. Nevertheless, the implementation of PSA remains constrained by data availability and quality, methodological complexity, computational demands, and challenges in communicating probabilistic outcomes to non-technical decision-makers. Nevertheless, emerging trends, including AI-driven distribution learning, machine-learning-based forecasting, and policy-guided probabilistic evaluation models, which suggest that the future of PSA in healthcare M&A valuation is shifting to a more generalized standardization. Lastly, PSA integration equips investors, acquirers, and policymakers with the maneuvering tools and means of navigating the high-risk, high-uncertainty healthcare environment more effectively. As probabilistic reasoning becomes further embedded in valuation structures, PSA will grow more credible and reliable as a framework for guiding M&A decision-making and delivering more robust, evidence-based acquisition outcomes in an ever-evolving global healthcare environment.

**References**

[1] Porter, M. E., & Lee, T. H. (2013). The strategy that will fix health care. *Harv Bus Rev*, *91*(10), 50-70.

[2] Maier, E., Reimer, U., & Wickramasinghe, N. (2021). Digital healthcare services. *Electronic Markets*, *31*(4), 743-746.

[3] Hermes, S., Riasanow, T., Clemons, E. K., Böhm, M., & Krcmar, H. (2020). The digital transformation of the healthcare industry: exploring the rise of emerging platform ecosystems and their influence on the role of patients. *Business Research*, *13*(3), 1033-1069.

[4] Ralph, R. (2015). Healthcare M&A: critical issues in today's fast-paced market. *Healthcare Financial Management*, *69*(9), 44-48.

[5] Briggs, A., Sculpher, M., & Claxton, K. (2006). *Decision modelling for health economic evaluation*. Oup Oxford.

[6] Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). *Methods for the economic evaluation of health care programmes*. Oxford University Press.

[7] Heath, C., Luff, P., & Svensson, M. S. (2003). Technology and medical practice. *Sociology of Health & illness*, *25*(3), 75-96.

[8] Singhal, S., Latko, B., & Martin, C. (2018). The future of healthcare: Finding the opportunities that lie beneath the uncertainty. *McKinsey on Healthcare*.

[9] Yeganeh, H. (2019). An analysis of emerging trends and transformations in global healthcare. *International Journal of Health Governance*, *24*(2), 169-180.

[10] Richardson, J. R. (2005). Priorities of health policy: cost shifting or population health. *Australia and New Zealand Health Policy*, *2*(1), 1.

[11] Burrell, D. N. (2024). Understanding healthcare cybersecurity risk management complexity. *Land Forces Academy Review*, *29*(1), 38-49.

[12] Maynard, A. D., & Scragg, M. (2019). The ethical and responsible development and application of advanced brain machine interfaces. *Journal of medical Internet research*, *21*(10), e16321.

[13] Chereches, M. C. (2024). Pharmaceutical Industry: Good and Bad. In *The Invisible Hand of Cancer: The Complex Force of Socioeconomic Factors in Oncology Today* (pp. 61-81). Cham: Springer International Publishing.

[14] Goes, J. B., & Zhan, C. (1995). The effects of hospital-physician integration strategies on hospital financial performance. *Health Services Research*, *30*(4), 507.

[15] Rahanuma, T., Sakhawat Hussain, T., Md Manarat Uddin, M., & Md Ashiqul, I. (2024). Healthcare Investment Trends: A Post-COVID Capital Market Analysis Investigating How Public Health Crises

Reshape Healthcare Venture Capital and M&A Activity. *American Journal of Technology Advancement*, *1*(1), 51-79.

[16] Garcia-Saisó, S., Marti, M., Regalia, F., Saavedra, J., Kallander, K., Labrique, A., ... & D'Agostino, M. (2024). Together towards tomorrow: partnerships powering the digital transformation of the health sector. *Revista Panamericana de Salud Pública*, *48*, e85.

[17] Dwivedi, S. P. (2024). Transforming healthcare: the power of computer vision and AI. *Revolutionising Medical Imaging with Computer Vision and Artificial Intelligence*, 33.

[18] Horwitz, J. R. (2024). Private Health Care in the United States and the Rise of Private Equity. *U. St. Thomas JL & Pub. Pol'y*, *18*, 27.

[19] Srivastava, R. K. (2020). Managing mergers and acquisitions in health care: A case study in the pharmaceutical sector. *International Journal of Healthcare Management*, *13*(sup1), 61-73.

[20] Jiang, H. J., Fingar, K. R., Liang, L., Henke, R. M., & Gibson, T. P. (2021). Quality of care before and after mergers and acquisitions of rural hospitals. *JAMA Network Open*, *4*(9), e2124662-e2124662.

[21] Burns, L. R., & Pauly, M. V. (2018). Transformation of the health care industry: curb your enthusiasm?. *The Milbank Quarterly*, *96*(1), 57-109.

[22] Kaplan, R. S., & Porter, M. E. (2011). How to solve the cost crisis in health care. *Harv Bus Rev*, *89*(9), 46-52.

[23] Jakobsen, J. B. Short-Term Value Creation in Healthcare Mergers & Acquisitions.

[24] Cimasi, R. J. (2014). *Healthcare valuation, the financial appraisal of enterprises, assets, and services* (Vol. 2). John Wiley & Sons.

[25] Nuijten, M., & Capri, S. (2024). Valuation of Medical Innovation Handling with Uncertainty and Risk. *Journal of Market Access & Health Policy*, *12*(3), 199-208.

[26] Abiodun, K., Adekoya, Y. F., Oladokun, P., Nwakaego, E. V., & Hamzat, L. (2024). A Predictive Risk Assessment Interface with Financial Valuation Metrics for Sector-Sensitive M&A Transactions in Healthcare and Telecommunications. *IJLRP-International Journal of Leading Research Publication*, *5*(11).

[27] Bonate, P. L. (2001). A brief introduction to Monte Carlo simulation. *Clinical pharmacokinetics*, *40*(1), 15-22.

[28] Smith, P., & Witter, S. (2001, May). Risk pooling in health care finance. In *Report Prepared für the World Bank Workshop „Resource Allocation and Purchasing in Health: Value for Money, Reaching the Poor."University of York, York/Washington DC (http://www. york. ac. uk/inst/che/pooling. pdf)*.

[29] Birch, S., & Gafni, A. (2003). Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results. *Health policy*, *64*(2), 207-219.

[30] Baio, G., & Dawid, A. P. (2015). Probabilistic sensitivity analysis in health economics. *Statistical methods in medical research*, *24*(6), 615-634.

[31] Qian, Z., Chen, X., Cole, A. P., Abdollah, F., Choueiri, T. K., Kibel, A. S., ... & Trinh, Q. D. (2024). Changes in prostate-specific antigen screening after the 2018 United States Preventive Services Task Force recommendations and through the COVID-19 pandemic. *European urology oncology*, *7*(1), 151-154.

[32] Moore, C., & Routhu, K. (2023). Leveraging Machine Learning Techniques for Predictive Analysis in Merger and Acquisition (M&A). *Available at SSRN 5103189*.

[33] Sendi, P., Walterscheidt, M., & Bornstein, M. M. (2025). Handling uncertainty in cost-effectiveness analysis in dental medicine: a systematic review with a focus on affordability and risk-aversion. *Cost Effectiveness and Resource Allocation*, *23*(1), 32.

[34] Brennan, A., & Akehurst, R. (2000). Modelling in health economic evaluation: What is its place? What is its value?. *Pharmacoeconomics*, *17*(5), 445-459.

[35] Simoens, S. (2009). Health economic assessment: a methodological primer. *International journal of environmental research and public health*, *6*(12), 2950-2966.

[36] Johannesson, M., & Jönsson, B. (1991). Economic evaluation in health care: is there a role for cost-benefit analysis?. *Health policy*, *17*(1), 1-23.

[37] Hutchens, B., & Pettit, J. (2009). Deal or No Deal? Outcomes from a Decade of Healthcare M&A. *Outcomes from a Decade of Healthcare M&A (September 22, 2009)*.

[38] Krishankumar, R., Sivagami, R., Saha, A., Rani, P., Arun, K., & Ravichandran, K. S. (2022). Cloud vendor selection for the healthcare industry using a big data-driven decision model with probabilistic linguistic information. *Applied Intelligence (Dordrecht, Netherlands)*, *52*(12), 13497.

[39] Baltussen, R., Leidl, R., & Ament, A. (1999). Real world designs in economic evaluation: bridging the gap between clinical research and policy-making. *Pharmacoeconomics*, *16*(5), 449-458.

[40] Chiou, P. Z., Herring, R. P., Oh, J., & Medina, E. (2024). Health impacts on the pathology workforce during mergers and acquisitions (M&A). *Journal of Clinical Pathology*, *77*(2), 98-104.